Clinical Trials Browser

Phase 2 × INDUSTRY × Nivolumab × Clear all

NCT07246863 2026-04-21

Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC

Phase 2 Recruiting

Other solid neoplasmThoracic

Metastatic Non-Squamous Non-Small Cell Lung Cancer

NCT03259867 2026-04-16

TATE-PD1

Phase 2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular, Stomach Neoplasms, Disease Progression

NCT02719613 2026-04-15

Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab

Phase 2 Completed

Multiple Myeloma

NCT06946797 2026-04-15

CheckMate-1533

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT07527858 2026-04-14

Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer

Phase 2 Not yet recruiting

Gastrointestinal

Advanced Microsatellite Stable Colorectal Cancer

NCT05257590 2026-04-13

CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma

Phase 2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular, Neoplasms

NCT06101134 2026-04-09

A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations

Phase 2 Active not recruiting

100 enrolled 11 charts

Melanoma, Neoplasm Metastasis, Patient Preference

NCT03505320 2026-04-03

ILUSTRO

Phase 2 Active not recruiting

Gastrointestinal

Neoplasms, Stomach Neoplasms

NCT03899155 2026-04-01

Pan Tumor Rollover Study

Phase 2 Recruiting

Neoplasms

NCT04785820 2026-03-27

A Study of Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus

Phase 2 Completed

190 enrolled 40 charts

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT06948448 2026-03-27

A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer

Phase 2 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT07494435 2026-03-27

Phase 2 Study of WGI-0301 Plus Nivolumab in Patients With HCC and RCC

Phase 2 Not yet recruiting

Carcinoma, Renal Cell

NCT07492680 2026-03-25

A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

Phase 2 Not yet recruiting

CNSDermatologicGastrointestinal

Brain Neoplasms, Melanoma, Pancreatic Neoplasms

NCT05633667 2026-03-17

VELOCITY-Lung

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06256328 2026-03-13

A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)

Phase 2 Active not recruiting

Gastrointestinal

Stomach Neoplasms

NCT06622941 2026-03-12

Study to ONO-4538 in Patients With Rhabdoid Tumor

Phase 2 Recruiting

Rhabdoid Tumor

NCT05926960 2026-03-09

PORTSIDE

Phase 2 Terminated

Melanoma, Skin Neoplasms

NCT05601752 2026-02-25

ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3)

Phase 2 Active not recruiting

Ovarian Neoplasms

NCT07432295 2026-02-25

Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)

Phase 2 Recruiting

Gastrointestinal

Adenocarcinoma Of Esophagus, Neoplasm Metastasis, Stomach Neoplasms

NCT03767348 2026-02-13

IGNYTE

Phase 2 Active not recruiting

DermatologicThoracic

Turcot syndrome, Carcinoma, Non-Small-Cell Lung, Melanoma

NCT03338790 2026-01-27

CheckMate 9KD

Phase 2 Completed

292 enrolled 21 charts

Prostatic Neoplasms

NCT05136677 2026-01-23

CheckMate 6DW

Phase 2 Completed

Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT03228667 2026-01-14

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

Phase 2 Active not recruiting

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Turcot syndrome, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

NCT04567615 2026-01-08

A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase Inhibitors

Phase 2 Completed

266 enrolled 28 charts

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT02985957 2025-12-22

CheckMate 650

Phase 2 Completed

351 enrolled 43 charts

Prostatic Neoplasms

NCT06059547 2025-12-11

Neoadjuvant Immunotherapy Combined With the Anti-GDF-15 Antibody Visugromab to Treat Muscle Invasive Bladder Cancer

Phase 2 Active not recruiting

Urinary Bladder Neoplasms

NCT02060188 2025-11-06

CheckMate142

Phase 2 Completed

385 enrolled 17 charts 2 FDA

GastrointestinalOther solid neoplasm

Microsatellite Unstable Colorectal Cancer

NCT07219459 2025-10-21

GDFATHERHCC01

Phase 2 Not yet recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT04623775 2025-10-20

A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

Phase 2 Active not recruiting

468 enrolled 24 charts

Carcinoma, Non-Small-Cell Lung

NCT05846646 2025-10-20

Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC

Phase 2 Terminated

6 enrolled 7 charts

GenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell

NCT04702880 2025-10-08

A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer

Phase 2 Active not recruiting

Small Cell Lung Carcinoma

NCT05350501 2025-09-29

CLAUDE

Phase 2 Terminated

1 enrolled 12 charts

Gastrointestinal

Colorectal Neoplasms

NCT06463665 2025-09-26

VIRO-25

Phase 2 Recruiting

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Vaccinia

NCT05934331 2025-09-12

A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study

Phase 2 Recruiting

Malignant Neoplasms of Digestive Organs

NCT03646123 2025-08-28

Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma

Phase 2 Terminated

255 enrolled 29 charts

Hodgkin Disease

NCT03645928 2025-06-19

LN-144

Phase 2 Recruiting

DermatologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma

NCT04698187 2025-06-11

CMP-001 in Combination With Nivolumab in Subjects With Advanced Melanoma

Phase 2 Terminated

44 enrolled 19 charts

Melanoma

NCT05169684 2025-06-10

A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer

Phase 2 Terminated

10 enrolled 15 charts

Neoplasm Metastasis, Prostatic Neoplasms, Castration-Resistant

NCT04566380 2025-06-03

ONO-4538 Phase II Rollover Study (ONO-4538-98)

Phase 2 Recruiting

Pan-tumor

NCT04704154 2025-04-18

A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors

Phase 2 Completed

175 enrolled 20 charts

CNSGastrointestinalHead & Neck

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Astrocytoma, Glioblastoma

NCT04907539 2025-04-16

A Study to Assess Efficacy of RXC004 +/- Nivolumab in Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, Colorectal Cancer After Progression on Standard of Care (SOC)

Phase 2 Completed

25 enrolled 22 charts

Gastrointestinal

Colorectal Neoplasms

NCT06094296 2025-04-16

A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

Phase 2 Terminated

1 enrolled 4 charts

Lung Neoplasms

NCT02582125 2025-03-24

ONO-4538 Study in Patients With Advanced Non-Small Cell Lung Cancer

Phase 2 Completed

Advanced Non-small Cell Lung Cancer

NCT05743270 2025-03-11

Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN

Phase 2 Withdrawn

Squamous Cell Carcinoma of Head and Neck

NCT02927769 2025-02-10

CheckMate 744

Phase 2 Completed

72 enrolled 24 charts

Hodgkin Disease

NCT03662659 2025-02-05

An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers

Phase 2 Completed

274 enrolled 19 charts

Gastrointestinal

Stomach Neoplasms

NCT04350463 2025-01-22

A Safety and Efficacy Study of CC-90011 in Combination With Nivolumab in Subjects With Advanced Cancers

Phase 2 Completed

92 enrolled 25 charts

Neoplasms, Small Cell Lung Carcinoma

NCT04382664 2025-01-14

UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma

Phase 2 Completed

156 enrolled 11 charts

Melanoma

NCT02175017 2024-12-09

ONO-4538 Study in Patients With Advanced Non-Small Cell Lung Cancer

Phase 2 Completed

104 enrolled 21 charts

Advanced Non-small Cell Lung Cancer (NSCLC)

NCT05846659 2024-12-09

Study of PULSAR-ICI +/- IMSA101 in Patients with Oligoprogressive Solid Tumor Malignancies

Phase 2 Terminated

Oligoprogressive